3/18
04:46 pm
arvn
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
Neutral
Report
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
3/18
04:40 pm
arvn
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Neutral
Report
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
3/4
07:17 am
arvn
Arvinas to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Arvinas to Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/4
07:00 am
arvn
Arvinas to Participate in Upcoming Investor Conferences
Low
Report
Arvinas to Participate in Upcoming Investor Conferences
3/3
07:00 am
arvn
Arvinas: Behind The Huge Rally [Seeking Alpha]
Low
Report
Arvinas: Behind The Huge Rally [Seeking Alpha]
3/1
05:49 am
arvn
Arvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
Low
Report
Arvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
2/29
09:10 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Barclays PLC from $26.00 to $60.00. They now have an "overweight" rating on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Barclays PLC from $26.00 to $60.00. They now have an "overweight" rating on the stock.
2/28
01:10 pm
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
2/28
10:26 am
arvn
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season? [Yahoo! Finance]
Neutral
Report
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season? [Yahoo! Finance]
2/28
09:13 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at BMO Capital Markets from $89.00 to $90.00. They now have an "outperform" rating on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at BMO Capital Markets from $89.00 to $90.00. They now have an "outperform" rating on the stock.
2/28
08:17 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $80.00 price target on the stock, down previously from $95.00.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $80.00 price target on the stock, down previously from $95.00.
2/28
08:17 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Wedbush from $33.00 to $59.00. They now have an "outperform" rating on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Wedbush from $33.00 to $59.00. They now have an "outperform" rating on the stock.
2/28
05:30 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
2/27
07:38 am
arvn
Arvinas GAAP EPS of -$2.53 misses by $1.38, revenue of $43.1M misses by $92.4M [Seeking Alpha]
Low
Report
Arvinas GAAP EPS of -$2.53 misses by $1.38, revenue of $43.1M misses by $92.4M [Seeking Alpha]
2/27
07:12 am
arvn
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/27
07:00 am
arvn
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Low
Report
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2/24
08:31 am
arvn
Arvinas (NASDAQ:ARVN) shareholders are still up 143% over 5 years despite pulling back 10% in the past week [Yahoo! Finance]
Medium
Report
Arvinas (NASDAQ:ARVN) shareholders are still up 143% over 5 years despite pulling back 10% in the past week [Yahoo! Finance]
2/21
01:41 pm
arvn
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now? [Yahoo! Finance]
Low
Report
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now? [Yahoo! Finance]
2/20
04:29 pm
arvn
Arvinas Announces Chief Financial Officer Transition [Yahoo! Finance]
Medium
Report
Arvinas Announces Chief Financial Officer Transition [Yahoo! Finance]
2/20
04:25 pm
arvn
Arvinas CFO Cassidy to Depart, Teel to Take Over on Interim Basis [MarketWatch]
Medium
Report
Arvinas CFO Cassidy to Depart, Teel to Take Over on Interim Basis [MarketWatch]
2/20
04:05 pm
arvn
Arvinas Announces Chief Financial Officer Transition
Medium
Report
Arvinas Announces Chief Financial Officer Transition
2/20
07:21 am
arvn
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease [Yahoo! Finance]
Medium
Report
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease [Yahoo! Finance]
2/20
07:00 am
arvn
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
Medium
Report
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
2/14
08:10 am
arvn
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer [Yahoo! Finance]
Medium
Report
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer [Yahoo! Finance]
2/14
08:00 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating. They now have a $55.00 price target on the stock, up previously from $36.00.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating. They now have a $55.00 price target on the stock, up previously from $36.00.